Cancer Vaccines: Three Platforms, One Winner for MRNA

Everyone wrote off Moderna after COVID. Revenue cratered from $19.3 billion in 2022 to under $2 billion projected for 2026. The flu vaccine missed its PDUFA. The norovirus Phase 3 stalled. The stock fell from $496 to $54.

The cancer vaccine pipeline says they are wrong. But the answer is not as simple as “mRNA cancer vaccines work.” Cancer vaccines are three different technologies at different stages of clinical development, with different manufacturing economics and different regulatory paths. The investor question is not whether cancer vaccines will work. The question is which platform commercializes first, and whether the company that gets there first is worth $20 billion or $100 billion.

Platform 1: mRNA Individualized Neoantigen Therapy (Moderna/Merck, BioNTech)

This is the platform most people mean when they say “cancer vaccine.” The process: sequence a patient’s tumor, identify mutations that produce neoantigens, proteins the immune system has never seen, design an mRNA encoding those neoantigens, manufacture it in a lipid nanoparticle, and inject it. The immune system learns to recognize and kill cells expressing those neoantigens. Every vaccine is custom-made for one patient. This is mass-customization healthcare.

Moderna and Merck are the frontrunners. Their candidate, intismeran autogene (mRNA-4157), is paired with Keytruda in the Phase 2b KEYNOTE-942 trial. The 5-year follow-up data presented at ASCO 2026 shows a 49% reduction in risk of recurrence or death (HR 0.51, 95% CI 0.29 to 0.89) and a 59% reduction in risk of distant metastasis or death (HR 0.41, 95% CI 0.20 to 0.84) compared to Keytruda alone in resected high-risk stage III/IV melanoma. The trial enrolled 157 patients (NCT03897881).

The Phase 3 INTerpath-001 trial (NCT05933577) in adjuvant melanoma is fully enrolled, with interim data expected in H2 2026. This is the binary catalyst. If the Phase 3 confirms the Phase 2b hazard ratio, intismeran becomes the first approved individualized cancer vaccine. Peak sales estimates range from $5 billion to $15 billion across melanoma and additional indications (lung, colorectal, hepatocellular). Read the full Moderna cancer vaccine analysis for the drug-specific deep dive.

BioNTech is the closest competitor. Their candidate, autogene cevumeran (BNT122), uses a different mRNA delivery system (lipoplex rather than lipid nanoparticle) but the same individualized neoantigen concept. The key data is a Phase 1 trial in resected pancreatic ductal adenocarcinoma published in Nature: 8 of 16 patients (50%) mounted vaccine-expanded T-cell responses, and responders had longer recurrence-free survival (not reached) versus non-responders (13.4 months, p=0.003). Pancreatic cancer is the hardest immunotherapy target, so even a 50% response rate with a signal toward efficacy is meaningful. But it is Phase 1 data in 16 patients, not Phase 3.

The manufacturing challenge for both is the binding constraint. Each vaccine requires tumor sequencing, neoantigen prediction algorithms, and custom mRNA manufacturing within approximately 6 to 9 weeks. BioNTech demonstrated that this is feasible within a clinical workflow in the pancreatic cancer study. But scaling from 16 patients to 100,000 patients per year is a manufacturing problem that neither company has solved yet. The infrastructure does not exist.

Platform 2: Peptide Vaccines (Off-the-Shelf, Shared Antigens)

Peptide vaccines target shared tumor antigens rather than patient-specific mutations. Instead of manufacturing a custom vaccine for each patient, you manufacture one vaccine for all patients with a given mutation. KRAS is the most studied target.

In July 2026, Johns Hopkins researchers reported that an experimental KRAS peptide vaccine generated immune responses in 18 of 20 participants (90%) at high risk for pancreatic cancer. This is an off-the-shelf approach: identify a common KRAS mutation, design a peptide that teaches T cells to recognize it, manufacture it at scale. No tumor sequencing or 9-week wait.

The trade-off is specificity. Individualized neoantigen vaccines target 20 to 34 patient-specific mutations. Peptide vaccines target one shared mutation. The immune response may be narrower. But the manufacturing cost is a fraction of the mRNA approach, and the scalability is orders of magnitude higher.

Peptide vaccines have been studied for decades with limited success. The HPV peptide vaccine ISA101 combined with nivolumab showed promising Phase 2 results in HPV-16-positive cancers. But no peptide cancer vaccine has achieved Phase 3 success and FDA approval. The platform is scientifically validated but commercially unproven.

Platform 3: Viral Vector Vaccines

Viral vector cancer vaccines use modified viruses to deliver tumor antigens. The virus infects cells, produces the antigen, and triggers an immune response. This is the same concept used in the Ebola vaccine and the Johnson and Johnson COVID vaccine, but applied to cancer.

This platform has the furthest to go. No viral vector cancer vaccine is in Phase 3 trials. The approach is largely preclinical or early Phase 1. The advantage is that viral vectors are a well-understood delivery platform with established manufacturing infrastructure. The disadvantage is that pre-existing immunity to the viral vector can neutralize the vaccine before it reaches the tumor.

The Gritstone Cautionary Tale

Gritstone Bio (GRTS) filed for Chapter 11 bankruptcy in October 2024 after its GRANITE individualized neoantigen vaccine missed Phase 2 endpoints in colorectal cancer. The company had $61.7 million in cash at the end of Q2 2024, insufficient to fund operations through year-end. The Phase 2 data sent the stock down 62% before the bankruptcy filing.

Gritstone’s failure is a reminder that cancer vaccines are binary risk. The Phase 2 GRANUTE data did not meet success thresholds, and the company could not raise additional capital. This is the risk that Moderna and BioNTech face if their Phase 3 trials fail. Gritstone had the same concept (individualized neoantigen vaccine) and a different delivery platform (self-amplifying mRNA and adenoviral vector). The technology was not enough. The data was.

Valuation: What Is the Cancer Vaccine Pipeline Worth?

Moderna at $54.82 ($21.75 billion market cap) is pricing in near-zero value for the cancer vaccine franchise. The company’s Q2 2026 revenue and norovirus/flu thesis, and the flu vaccine PDUFA is the near-term revenue bridge. The market is valuing Moderna as a declining COVID vaccine company with a failed flu program and a stalled norovirus program. The cancer vaccine pipeline is essentially free option value at current prices.

If INTerpath-001 reads out positive in H2 2026, the stock re-rates immediately. A 49% RFS risk reduction in a Phase 3 confirmatory trial, if it holds, supports peak sales of $5 to $15 billion across indications. At the low end, $5 billion in peak sales at a 4x price-to-sales multiple, comparable to early-stage oncology launches, implies $20 billion in pipeline value, roughly the current market cap. At the high end, $15 billion in peak sales implies $60 billion in pipeline value, nearly tripling the stock. The range between $20B and $60B is the cancer vaccine option value.

BioNTech at $90.58 ($23.35 billion market cap) is in a similar position. The company has more cash than Moderna (approximately EUR 17 billion versus Moderna’s $6.9 billion) and a broader oncology pipeline including CAR-T and bispecific antibodies. The cancer vaccine program is one piece of a diversified oncology platform. Read the Moderna vs BioNTech platform comparison for the comp analysis.

Merck at $130.20 ($321.6 billion market cap) is the third player but the least interesting from a cancer vaccine investment perspective. Keytruda generated $25 billion in 2025 revenue. Even if intismeran adds $5 to $15 billion in peak sales, that is 2% to 5% of Merck’s revenue base. The cancer vaccine is a pipeline extension for Merck, not a stock-moving catalyst. The same large-cap immateriality framing that applies to most pharma catalysts applies here. Merck is the partner, not the pure play.

The Combination Approach

Every cancer vaccine trial is a combination trial. The vaccines are not designed as monotherapy. They are designed to work with checkpoint inhibitors, the drugs that release the brakes on the immune system. The vaccine teaches T cells to recognize the tumor, and the checkpoint inhibitor prevents the tumor from suppressing the T-cell response. This is why ADCs and checkpoint inhibitors are the foundation, and cancer vaccines are the third leg of modern immuno-oncology.

The implication for investors is that cancer vaccine adoption depends on checkpoint inhibitor adoption. Keytruda is the default partner for Moderna’s intismeran. If Keytruda’s patent cliff in 2028 changes the pricing dynamics of checkpoint inhibitors, it affects the cancer vaccine combination economics too. The two are linked.

Risks

The primary risk is Phase 3 failure. Phase 2b data in 157 melanoma patients, no matter how durable at 5 years, is not Phase 3 data. The history of oncology drug development is full of Phase 2 signals that failed to confirm in Phase 3. Gritstone’s GRANITE is the most recent cancer vaccine example. If INTerpath-001 misses its primary endpoint, Moderna loses the pipeline asset that justifies its market cap above its declining COVID revenue base.

The secondary risk is manufacturing. Even with Phase 3 success, the FDA will need to evaluate whether individualized mRNA manufacturing can meet current Good Manufacturing Practice standards at scale. No regulatory pathway exists for mass-customized biologics. The FDA will need to create one, and that process could delay approval beyond the PDUFA date.

The tertiary risk is time. Phase 3 readouts for intismeran are expected in H2 2026, but the INTerpath program spans multiple indications. Melanoma is first. Lung, colorectal, and hepatocellular carcinoma trials are enrolling. Full commercialization across a broad indication set is a 2028 to 2030 timeline. This is a multi-year hold, not a near-term catalyst play. Investors need to size positions for binary multi-year risk, as outlined in the biotech investing framework.

Verdict

The cancer vaccine pipeline is real, but it is not a monolith. The mRNA individualized neoantigen platform (Moderna/Merck, BioNTech) has the closest path to approval, with a 49% RFS risk reduction (HR 0.51) in Phase 2b melanoma. The peptide platform is more scalable but unproven in Phase 3. The viral vector platform is years behind.

Moderna at $21.75B is the highest-conviction trade. The market is pricing the cancer vaccine pipeline at zero. If INTerpath-001 confirms the Phase 2b hazard ratio, the stock has 2x to 3x upside on pipeline re-rating alone. If it fails, the stock has 30 to 50% downside. That is the binary setup. Size for the risk. The Q2 2026 earnings confirmed the near-term revenue picture: $145 million in revenue, $782 million net loss, $6.9 billion in cash, 2.5 years of runway. The clock is running.

BioNTech at $23.35B is the lower-risk, lower-reward version of the same trade. More cash, broader pipeline, same cancer vaccine concept, slightly different delivery platform. The pancreatic cancer Phase 1 data is scientifically important but clinically early. The near-term catalysts are further out.

Buy MRNA for the cancer vaccine option value. The stock is pricing in failure. The Phase 2b data suggests otherwise. INTerpath-001 interim data in H2 2026 is the binary catalyst that determines whether Moderna is a $20 billion or $60 billion company.